Head to Head Contrast: Scienture (SCNX) vs. Its Peers

Scienture (NASDAQ:SCNX) is one of 248 publicly-traded companies in the “MED – DRUGS” industry, but how does it contrast to its competitors? We will compare Scienture to similar companies based on the strength of its analyst recommendations, institutional ownership, dividends, risk, earnings, valuation and profitability.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Scienture and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1	0	0	0	1.00
Scienture Competitors	1957	3689	9732	395	2.54

As a group, “MED – DRUGS” companies have a potential upside of 72.49%. Given Scienture’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Scienture has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Scienture and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Scienture	$128,202.00	$9.07 million	-0.25
Scienture Competitors	$29.96 billion	$56.85 million	3.16

Scienture’s competitors have higher revenue and earnings than Scienture. Scienture is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Scienture and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scienture	-10,364.22%	-24.47%	-19.30%
Scienture Competitors	-19,411.49%	-96.06%	-16.45%

Risk and Volatility

Scienture has a beta of 3.04, meaning that its stock price is 204% more volatile than the S&P 500. Comparatively, Scienture’s competitors have a beta of 1.27, meaning that their average stock price is 27% more volatile than the S&P 500.

Institutional & Insider Ownership

5.7% of Scienture shares are held by institutional investors. Comparatively, 43.8% of shares of all “MED – DRUGS” companies are held by institutional investors. 21.4% of Scienture shares are held by insiders. Comparatively, 13.3% of shares of all “MED – DRUGS” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Scienture competitors beat Scienture on 9 of the 13 factors compared.

Scienture Company Profile

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.